Stem Cells International

Stem Cells International / 2016 / Article
Special Issue

Vascular Diseases and Metabolic Disorders

View this Special Issue

Research Article | Open Access

Volume 2016 |Article ID 8160318 | https://doi.org/10.1155/2016/8160318

Yuze Li, Dianzhong Li, Jinfeng Zhang, Shurui Liu, Haijun Chen, Kun Wu, "Association between Toll-Like Receptor 4 and Occurrence of Type 2 Diabetes Mellitus Susceptible to Pulmonary Tuberculosis in Northeast China", Stem Cells International, vol. 2016, Article ID 8160318, 6 pages, 2016. https://doi.org/10.1155/2016/8160318

Association between Toll-Like Receptor 4 and Occurrence of Type 2 Diabetes Mellitus Susceptible to Pulmonary Tuberculosis in Northeast China

Academic Editor: Yingmei Feng
Received02 Dec 2015
Revised03 Mar 2016
Accepted13 Mar 2016
Published31 Mar 2016

Abstract

The purpose of this study is to explore why type 2 diabetes mellitus (T2DM) patients are susceptible to pulmonary tuberculosis through detection of serum Toll-like receptor 4 (TLR4), an important immune-related receptor, especially in terms of content and TLR4 gene polymorphism. Patients with T2DM complicated by pulmonary tuberculosis (T2DMTB) were selected as the case group and T2DM patients without tuberculosis were selected as the control group. Forty patients in each group were randomly selected and their serum TLR4 levels were detected and compared. Determination of six sites of TLR4 gene polymorphism was carried out in 238 T2DMTB patients and 310 patients with T2DM, and results showed that the serum TLR4 content of the T2DMTB group was significantly lower than that of the T2DM group (). The six sites of TLR4 gene polymorphism did not show significant associations with T2DMTB risk. No statistically significant differences in genotype distributions were observed between T2DMTB patients and patients with T2DM when studied using the recessive and dominant genetic models. How two diseases with contradictory nutritional statuses can occur in the same person is difficult to explain from environmental factors perspective alone. Future research should study the causes of T2DMTB from the perspective of genetics.

1. Introduction

The prevalence of type 2 diabetes mellitus (T2DM) complicated by tuberculosis (TB) (T2DMTB) is rapidly increasing, resulting in detrimental effects on the economy and human health.

Clinical symptoms reveal that environmental factors play important roles in T2DM and TB. Because T2DMTB may be attributed to multiple causes, clinical experience indicates the traditional perspective that the two diseases are related in terms of nutrition. TB is associated with malnutrition, while T2DM is associated with excess nutrients. Thus, environmental factors, among which nutrition is one of the most important, alone, cannot explain the pathogenesis of two seemingly conflicting diseases occurring simultaneously in the same individual. In this case, genetic factors may be responsible for the development of T2DMTB [13], but we are not the first who are aware of host genetic factors that are important to determine the risk of type 2 diabetes mellitus complicated by tuberculosis. García-Elorriaga et al. [4] analyzed the association of inflammatory cytokine polymorphisms and T2DMTB in Mexico.

Toll-like receptor 4 (TLR4), a pattern recognition receptor, can recognize pathogen-associated molecular patterns (PAMPs) [5] and exacerbate and release inflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IFN-γ [6]. Mycobacterium tuberculosis presents liposaccharides (LPS), a type of PAMP. When TLR4 recognizes the LPS of M. tuberculosis, inflammatory cytokines are induced and released by the pathway of TLR4 [79]. This pathway is an important element in the innate immune system of the human body. TLR4, as an important mediator of inflammation, can recognize a variety of pathogens, including Gram-negative and Gram-positive bacteria [10]. Previous studies have shown that human TLR4 is a potentially important gene that may affect the onset of T2DM [1113]. The receptor may be related to susceptibility to some infections that can induce diseases such as TBs [1418]. To date, no study has yet reported the association between TLR4 gene polymorphisms and the risk of T2DMTB in the Chinese population.

We believe that TLR4 gene polymorphisms are a good starting point for studying T2DMTB. To be able to establish preventive measures for high-risk people as far as possible, in this study, we investigate the relationship between TLR4 gene polymorphisms and T2DMTB risk in Northeast China.

2. Material and Methods

2.1. Study Subject and Sample Collection

We recruited 238 cases with T2DMTB as the case group and 310 cases with T2DM as the control group. T2DMTB patient information was obtained from the Fourth Medical Ward, Heilongjiang Province Tuberculosis Control Center, from September 2013 to June 2015. T2DM patient information was obtained from the Second Department of Outpatient Services, Heilongjiang Province Tuberculosis Control Center, from September 2013 to November 2014.

Subjects with a history of blood-transmitted diseases, such as AIDS, hepatitis B, hepatitis C, or other endocrine diseases, were excluded from this study. Blood samples were taken from the patients, and DNA was obtained and stored in 193 K. Both doctors and study subjects provided consent to participate in this work, and the Ethics Committee of Harbin Medical University approved of this research.

2.2. Immunohistochemical Method

To determine whether serum TLR4 levels were consistent with the gene expression level, 40 serum samples were collected from the T2DMTB group and T2DM group, respectively, according to the principle of random. Serum TLR4 contents were detected by using an immunohistochemical method following the manufacturer’s instructions (Beijing Cheng Lin Biological Technology Co., Ltd.).

2.3. Tag SNP Selection and Genotyping

Tag SNPs of TLR4 gene were evaluated and selected by using the HapMap database (https://hapmap.ncbi.nlm.nih.gov/) with the following criterion: a minor allele frequency (MAF) > 0.05 in the Chinese Han population in the National Center of Biotechnology Information Database; linkage disequilibrium (LD) blocks were established by using Chinese LD maps and . Six tag SNPs representing the genetic information of TLR4 were selected for genotyping: rs1927914 located in the promoter region; rs11536879, rs1927911, and rs1927907 located in the intron region; and rs11536889 and rs7873784 located in the 3′-UTR region.

According to the manufacturer’s instructions, genomic DNA was extracted from peripheral blood using a Tiangen DNA Blood Mini kit (Tiangen Biotech Co., Ltd., Beijing, China). All SNPs were genotyped using fluorogenic 5′-nuclease assay (TaqMan SNP Genotyping Assay, Applied Biosystems, Foster City, CA, USA). For quality control, 20% of all of the samples were performed in delicate form randomly for each SNP. The concordance rate of these repeated samples was 100%.

2.4. Statistical Analysis

Numerical data are expressed as mean ± SD. Student’s t-test was performed to analyze differences between the T2DMTB and T2DM groups.

Fisher’s exact test was used to evaluate the Hardy-Weinberg equilibrium (HWE) in the subjects. The chi-square test or Fisher’s exact test was used to identify statistical differences in the distributions of clinic pathological characteristics. Univariate and multivariate unconditional logistic regression were used to estimate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs), all of which measured the associations between the risk factors of T2DMTB compared with T2DM. Two-sided was considered as statistically significant. Statistical analysis was carried out by using SAS software (version 9.1.3, SAS Institute, Cary, NC).

3. Results

3.1. Demographic Characteristics

A total of 548 people participated in this study, including 238 cases of T2MDTB and 310 cases of T2MD. Among the patients, 338 were male and 210 were female. The mean ages of T2DMTB and T2DM patients were 51.97 ± 11.87 years and 58.73 ± 11.46 years, respectively. The demographic characteristics of the patients are shown in Table 1.


VariableT2DMTBT2DMTotal value

Age
 ⩽5010468172<0.0001
 50–6073108181
 60–704580125
70165470
Gender
 Male1671713380.0003
 Female71139210
BMI
 ⩽18.535843<0.0001
 18.5–2411264176
2491238329
Smoking
 Yes13286218<0.0001
 No106224330
Drinking
 Yes108942020.0003
 No130216346
Glucose
 <5.01213250.0857
 5.0–7.24888136
 >7.2178209387
Insulin use
 Use112196308<0.0001
 No use126112238
 Unclear022
Hypoglycemic drug use
 Use45224269<0.0001
 No use19380273
 Unclear066

3.2. Serum TLR4 Levels of Patients with T2DMTB and Patients with T2DM

The serum TLR4 levels of subjects with T2DMTB were significantly lower than those of subjects suffering from T2DM (). No differences in the basic characteristics of the participants, including gender () and age (), were observed (Table 2).


VariableT2DMTBT2DM value

Gender (male/female)40 (20/20)40 (25/15)0.260
Age (years)0.631
TLR4 (ng/mL)<0.0001

3.3. Distributions of SNP Genotypes between Patients with T2DMTB and Patients with T2DM

Genotype distributions did not show statistically significant deviations from HWE for all SNPs in this study (Table 3).


T2DMTB
No. (%)
T2DM
No. (%)
valueHardy-Weinberg
value

rs7873784
 GG243 (86.17)236 (83.69)0.190.560.46
 GC35 (12.41)45 (15.96)
 CC4 (1.42) 1 (0.35)
rs11536889
 GG176 (61.97)181 (64.41)0.830.810.37
 GC93 (32.75)86 (30.61)
 CC15 (5.28)14 (4.98)
rs1927914
 TT90 (31.91)102 (36.17)0.500.530.47
 CT145 (51.42)140 (49.65)
 CC47 (16.67)40 (14.18)
rs1927911
 TT97 (34.28)96 (34.16)0.482.920.09
 CT139 (49.12)148 (52.67)
 CC47 (16.61)37 (13.17)
rs1927907
 GG145 (51.24)147 (52.31)0.962.120.15
 AG123 (43.46)119 (42.35)
 AA15 (5.30)15 (5.34)
rs11536879
 AA230 (82.44)215 (77.62)0.201.040.31
 AG41 (14.70)56 (20.22)
 GG 8 (2.87)6 (2.17)

3.4. Distribution of Allelic Genes of SNPs between Patients with T2DMTB and Patients with T2DM

The distributions of allelic genes of six SNPs of the TLR4 gene were not statistically significant between patients with T2DMTB and patients with T2DM. Details of these distributions are summarized in Table 4.


SNP Allelic genesT2DMTB T2DM value
No.%No.%

rs7873784G allele52192.3651791.670.74
C allele437.64 47 8.33

rs11536889G allele44578.3544879.720.61
C allele12321.6511420.28

rs1927914T allele32557.6234460.990.43
C allele22942.3822039.01

rs1927911T allele33358.8334060.500.59
C allele23341.1722239.50

rs1927907G allele41372.9741373.490.89
A allele15327.0314926.51

rs11536879A allele50189.7848687.730.30
G allele5710.226812.27

3.5. SNPs and T2DMTB Risk

The SNPs of TLR4 were not significantly associated with T2DMTB risk. No significant differences in genotype distributions between patients with T2DMTB and patients with T2DM were observed using the recessive and dominant genetic models (Table 5). However, potential trends may provide useful information for future studies. In rs7873784, compared with the GG genotype, the GC genotype presented lower risks of T2DMTB (, 95% CI: 0.42–1.14, ). In rs11536879, AG genotype carriers showed decreased risk of T2DMTB compared with the GG genotype (, 95% CI: 0.43–1.08, ).


GenotypeCrude OR (95% CI) valueAdjusted OR (95% CI) value

rs7873784
 GG1.001.00
 GC0.76 (0.47–1.22)0.250.69 (0.42–1.14)0.15
 CC3.89 (0.43–35.01)0.233.16 (0.33–30.74)0.32
 CC/(GG + GC)4.04 (0.45–36.41)0.213.34 (0.34–32.38)0.30
 (GC + CC)/GG0.82 (0.52–1.31)0.410.75 (0.46–1.22)0.25
rs11536889
 GG1.001.00
 GC1.12 (0.78–1.60)0.541.04 (0.71–1.51)0.85
 CC1.11 (0.52–2.36)0.791.08 (0.49–2.39)0.85
 CC/(GG + GC)1.07 (0.51–2.26)0.861.07 (0.49–2.34)0.87
 (GC + CC)/GG1.12 (0.79–1.57)0.531.04 (0.73–1.49)0.82
rs1927914
 TT1.001.00
 CT1.17 (0.81–1.69)0.391.25 (0.85–1.84)0.25
 CC1.33 (0.80–2.21)0.271.35 (0.80–2.29)0.27
 CC/(TT + CT)1.21 (0.77–1.91)0.421.18 (0.73–1.91)0.49
 (CT + CC)/TT1.21 (0.85–1.71)0.291.28 (0.89–1.84)0.19
rs1927911
 TT1.001.00
 CT0.93 (0.65–1.34)0.700.93 (0.63–1.36)0.71
 CC1.26 (0.75–2.10)0.381.22 (0.72–2.09)0.46
 CC/(TT + CT)1.31 (0.82–2.09)0.251.28 (0.79–2.08)0.36
 (CT + CC)/TT1.00 (0.70–1.41)0.980.99 (0.69–1.43)0.96
rs1927907
 GG1.001.00
 AG1.05 (0.75–1.47)0.791.03 (0.72–1.48)0.86
 AA1.01 (0.48–2.15)0.970.95 (0.44–2.05)0.89
 AA/(GG + AG)0.99 (0.48–2.07)0.980.93 (0.44–1.99)0.85
 (AG + AA)/GG1.04 (0.75–1.45)0.801.02 (0.72–1.44)0.90
rs11536879
 AA1.001.00
 AG0.68 (0.44–1.07)0.090.68 (0.43–1.08)0.10
 GG1.25 (0.43–3.65)0.691.35 (0.45–4.04)0.59
 GG/(AA + AG)1.33 (0.46–3.89)0.601.44 (0.48–4.31)0.51
 (AG + GG)/AA0.74 (0.49–1.12)0.160.75 (0.48–1.15)0.19

Note. Age, gender, BMI, smoking, drinking, insulin use, and hypoglycemic drug use were adjusted.

4. Discussion

A previous study showed that patients with T2DM demonstrated four to eight times increased risk of tuberculosis compared to patients without T2DM. For instance, TB in T2DM patients was 5 times more prevalent than in non-T2DM patients in some regions in the USA, 5.4 times more prevalent than in non-T2DM patients in Australia, and 6.8 times more prevalent than in non-T2DM patients in Mexico [4].

In the clinic, we discovered that T2DMTB patients present uneven changes in inflammatory cytokines such as TNF-α and IFN-γ. Clinical examination of simple TB yielded a positive IFN-γ test, but the results of nearly all patients with T2DMTB were negative. TLR4 is an important element of the endogenic immune system and it can induce and release inflammatory cytokines [5]. TLR4 is an important element of the innate immune system of the human body. Thus, we hypothesize that serum TLR4 exhibits obvious changes in T2DMTB patients. We examined TLR4 serum levels in patients with T2DMTB and patients T2DM to determine whether TLR4 is involved in the susceptibility of T2DM patients suffering from TB in Northeast China. While no study has yet proven that TLR4 polymorphisms are related to T2DMTB or T2DM, other studies [1922] indicate that TLR4 polymorphisms present statistically significant differences between healthy people and patients with TB.

Our study results are different from those of Wu et al. [23], especially in terms of the frequencies of the GG genotype of SNP rs7873784 in TLR4 (OR = 2.136; 95% CI: 1.312–3.478) and the CC genotype of rs3764879 in TLR8 (OR = 1.982; 95% CI: 1.292–3.042). It was also significantly higher in the TB group than in the healthy group. Arji et al. [24] found TLR4 interactions influencing protection against TB in Moroccan patients. The present work and that of Jahantigh et al. [25] both demonstrated no significant relation between TLR4 and TLR9 polymorphisms and TB. Sánchez et al. [26] reported that they did not find any association between TLR4 polymorphic variants. These findings suggest that the gene polymorphisms were not involved in any risk factor for pulmonary TB in the Colombian population [26]. The same result was obtained by Xue et al. [27], who discovered that these polymorphisms were rare in the Southeastern Chinese population and not linked to susceptibility to TB. Newport et al. [28] also have studied that, but result was that no association between TLR4 Asp299Gly and TB was observed.

The result of our study showed that it was negative. The reasons behind this result are first the size of the sample which was not enough. The second one is the geographic regions and genetic factors, because we were focused on the people of Northeast China in our work just only.

The purpose of this study is to determine why patients with T2DM easily develop pulmonary TB. Thus, we did not detect TLR4 gene polymorphisms in healthy cases and we did not compare changes in TLR4 gene polymorphisms among healthy cases, patients with T2DM, and patients with T2DMTB. Changes in TLR4 gene polymorphisms may have already occurred in most patients with T2DM. In this case, a false negative result may appear if a comparison was carried out between T2DM patients and patients suffering from T2DMTB only. Such a phenomenon would also confirm some reports that T2DM is characterized by chronic inflammation.

Some studies have recently mentioned that the risk genotypes of rs1927914 are significantly linked with diabetic foot ulcers [29]; the research team of Singh [30] also found that the combined genotype risks of TLR4 SNPs rs10759931 (odds ratio [OR] 1.50, ) and rs1927914 (OR 1.48, ) were significantly linked to retinopathy in T2DM. These works support the idea that T2DM is a chronic inflammatory disease. It is possible that T2DM patients already had TLR4 gene polymorphism. Therefore, we considered these points as the third reason.

Two groups of patients were included in our study. For each group, we concerned about the changing of TLR4 gene polymorphism and no changing of TLR4 levels in the blood. The reason of that was hidden behind the changing in the TLR4 gene, because serum TLR4 is a sensitivity index but not a specific index. Chronic inflammation could directly lead to changes in TLR4 in the blood or other gene polymorphisms that could lead to TLR4 changes in the blood. Our study was limited by considering just TLR4 gene polymorphisms. Other inflammatory gene polymorphisms that promote development of T2DMTB may exist.

The results of this study reveal that TLR4 changes at the molecular level are insignificant because the changes at the gene level may be not significant. Our results also demonstrated no significant link between the six SNPs of TLR4 studied in this work and the susceptibility of patients with T2DMTB in Northeast China. Future studies may be performed to determine the causes of T2DMTB from the perspective of genetics. We aim to determine the marker gene polymorphism in T2DM and show how it can be complicated by TB.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

References

  1. M. Crook, “Type 2 diabetes mellitus: a disease of the innate immune system? An update,” Diabetic Medicine, vol. 21, no. 3, pp. 203–207, 2004. View at: Publisher Site | Google Scholar
  2. H. Kolb and T. Mandrup-Poulsen, “An immune origin of type 2 diabetes?” Diabetologia, vol. 48, no. 6, pp. 1038–1050, 2005. View at: Publisher Site | Google Scholar
  3. G. G. L. Biondi-Zoccai, A. Abbate, G. Liuzzo, and L. M. Biasucci, “Atherothrombosis, inflammation, and diabetes,” Journal of the American College of Cardiology, vol. 41, no. 7, pp. 1071–1077, 2003. View at: Publisher Site | Google Scholar
  4. G. García-Elorriaga, L. Vera-Ramírez, G. del Rey-Pineda, and C. González-Bonilla, “−592 and −1082 interleukin-10 polymorphisms in pulmonary tuberculosis with type 2 diabetes,” Asian Pacific Journal of Tropical Medicine, vol. 6, no. 7, pp. 505–509, 2013. View at: Publisher Site | Google Scholar
  5. C. A. Janeway Jr. and R. Medzhitov, “Innate immune recognition,” Annual Review of Immunology, vol. 20, pp. 197–216, 2002. View at: Publisher Site | Google Scholar
  6. R. Medzhitov and C. Janeway Jr., “Innate immunity,” The New England Journal of Medicine, vol. 343, no. 5, pp. 338–344, 2000. View at: Publisher Site | Google Scholar
  7. S. T. Qureshi, L. Larivière, G. Leveque et al., “Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4),” Journal of Experimental Medicine, vol. 189, no. 4, pp. 615–625, 1999. View at: Publisher Site | Google Scholar
  8. L. A. J. O'Neill, K. A. Fitzgerald, and A. G. Bowie, “The Toll-IL-1 receptor adaptor family grows to five members,” Trends in Immunology, vol. 24, no. 6, pp. 286–289, 2003. View at: Publisher Site | Google Scholar
  9. D. Ning and Y. Yongming, “Toll-like receptors immunology research progress,” Infection, Immunity & Repair, vol. 9, no. 3, pp. 177–180, 2008. View at: Google Scholar
  10. A. Aderem and R. J. Ulevitch, “Toll-like receptors in the induction of the innate immune response,” Nature, vol. 406, no. 6797, pp. 782–787, 2000. View at: Publisher Site | Google Scholar
  11. Y.-C. Lu, W.-C. Yeh, and P. S. Ohashi, “LPS/TLR4 signal transduction pathway,” Cytokine, vol. 42, no. 2, pp. 145–151, 2008. View at: Publisher Site | Google Scholar
  12. M. Buraczynska, I. Baranowicz-Gaszczyk, J. Tarach, and A. Ksiazek, “Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes,” Human Immunology, vol. 70, no. 2, pp. 121–124, 2009. View at: Publisher Site | Google Scholar
  13. Z.-S. Jiang, S.-X. Wang, H.-X. Jia, J. Wang, and Y.-T. Liu, “Association of toll-like receptor 4 polymorphisms with type 2 diabetes mellitus,” Inflammation, vol. 36, no. 1, pp. 251–257, 2013. View at: Publisher Site | Google Scholar
  14. C. Maldonado-Bernal, O. A. Trejo-de la, M. E. Sánchez-Contreras, N. Wacher-Rodarte, J. Torres, and M. Cruz, “Low frequency of Toll-like receptors 2 and 4 gene polymorphisms in Mexican patients and their association with type 2 diabetes,” International Journal of Immunogenetics, vol. 38, no. 6, pp. 519–523, 2011. View at: Publisher Site | Google Scholar
  15. F. F. Yuan, K. Marks, M. Wong et al., “Clinical relevance of TLR2, TLR4, CD14 and FcγRIIA gene polymorphisms in Streptococcus pneumoniae infection,” Immunology and Cell Biology, vol. 86, no. 3, pp. 268–270, 2008. View at: Publisher Site | Google Scholar
  16. C. Guarner-Argente, E. Sánchez, S. Vidal et al., “Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 11, pp. 1192–1199, 2010. View at: Publisher Site | Google Scholar
  17. M. Surbatovic, K. Grujic, B. Cikota et al., “Polymorphisms of genes encoding tumor necrosis factor-alpha, interleukin-10, cluster of differentiation-14 and interleukin-1ra in critically ill patients,” Journal of Critical Care, vol. 25, no. 3, pp. 542.e1–542.e8, 2010. View at: Publisher Site | Google Scholar
  18. A. Q. Zhang, C. L. Yue, W. Gu et al., “Association between CD14 promoter -159C/T polymorphism and the risk of sepsis and mortality: a systematic review and meta-analysis,” PLoS ONE, vol. 8, no. 8, Article ID e71237, 2013. View at: Publisher Site | Google Scholar
  19. E. Lorenz, M. Jones, C. Wohlford-Lenane et al., “Genes other than TLR4 are involved in there sponse to inhaled LPS,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 281, no. 5, pp. 1106–1114, 2001. View at: Google Scholar
  20. N. C. Arbour, E. Lornz, B. C. Schutte et al., “TLR4 mutations are associated with endotoxin hyporesponsiveness in humans,” Nature Genetics, vol. 25, no. 2, pp. 187–191, 2000. View at: Google Scholar
  21. T. E. West, W. Chierakul, N. Chantratita et al., “Toll-like receptor 4 region genetic variants are associated with susceptibility to melioidosis,” Genes and Immunity, vol. 13, no. 1, pp. 38–46, 2012. View at: Publisher Site | Google Scholar
  22. Y. F. Qing, J. G. Zhou, Q. B. Zhang et al., “Association of TLR4 Gene rs2149356 polymorphism with primary gouty arthritis in a case-control study,” PLoS ONE, vol. 8, no. 5, Article ID e64845, 2013. View at: Publisher Site | Google Scholar
  23. L. Wu, Y. Hu, D. Li, W. Jiang, and B. Xu, “Screening toll-like receptor markers to predict latent tuberculosis infection and subsequent tuberculosis disease in a Chinese population,” BMC Medical Genetics, vol. 16, no. 1, article 19, 2015. View at: Publisher Site | Google Scholar
  24. N. Arji, M. Busson, G. Iraqi et al., “Genetic diversity of TLR2, TLR4, and VDR loci and pulmonary tuberculosis in moroccan patients,” Journal of Infection in Developing Countries, vol. 8, no. 4, pp. 430–440, 2014. View at: Publisher Site | Google Scholar
  25. D. Jahantigh, S. Salimi, R. Alavi-Naini, A. Emamdadi, H. Owaysee Osquee, and F. Farajian Mashhadi, “Association between TLR4 and TLR9 gene polymorphisms with development of pulmonary tuberculosis in Zahedan, Southeastern Iran,” The Scientific World Journal, vol. 2013, Article ID 534053, 7 pages, 2013. View at: Publisher Site | Google Scholar
  26. D. Sánchez, C. Lefebvre, J. Rioux, L. F. García, and L. F. Barrera, “Evaluation of Toll-like receptor and adaptor molecule polymorphisms for susceptibility to tuberculosis in a Colombian population,” International Journal of Immunogenetics, vol. 39, no. 3, pp. 216–223, 2012. View at: Publisher Site | Google Scholar
  27. Y. Xue, Z. Q. Zhao, H. J. Wang et al., “Toll-like receptors 2 and 4 gene polymorphisms in a southeastern Chinese population with tuberculosis,” International Journal of Immunogenetics, vol. 37, no. 2, pp. 135–138, 2010. View at: Publisher Site | Google Scholar
  28. M. J. Newport, A. Allen, A. A. Awomoyi et al., “The toll-like receptor 4 Asp299Gly variant: no influence on LPS responsiveness or susceptibility to pulmonary tuberculosis in The Gambia,” Tuberculosis, vol. 84, no. 6, pp. 347–352, 2004. View at: Publisher Site | Google Scholar
  29. S. Singh, V. K. Singh, N. K. Agrawal, S. K. Gupta, and K. Singh, “Association of toll-like receptor 4 polymorphisms with diabetic foot ulcers and application of artificial neural network in DFU risk assessment in type 2 diabetes patients,” BioMed Research International, vol. 2013, Article ID 318686, 9 pages, 2013. View at: Publisher Site | Google Scholar
  30. K. Singh, S. Kant, V. K. Singh, N. K. Agrawal, and S. K. Gupta, “Toll-like receptor 4 polymorphisms and their haplotypes modulate the risk of developing diabetic retinopathy in type 2 diabetes patients,” Molecular Vision, vol. 20, pp. 704–713, 2014. View at: Google Scholar

Copyright © 2016 Yuze Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views1031
Downloads527
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.